This month’s feature article is the first publication of the 2017 global pharmaceutical industry statistics from which the global and US rankings of the top 15 drug companies are derived. Comparisons are made with historical data to show how different company strategies have evolved. In addition, an analysis of the evolution of biopharmaceuical drugs has been made, together with a key sub-set, namely drugs derived from antibody technology, which now represent 12% of the entire market. Two more drugs joined the $100bn club in 2017.
04 Apr 2018
The Monthly
Time Finance plc (TIME:LON), 37.2 | Abzena (ABZA:LON), 0 | Advanced Oncotherapy Plc (AVO:LON), 1.9 | Allergy Therapeutics plc (AGY:LON), 2.7 | Alliance Pharma plc (APH:LON), 37.2 | Arbuthnot Banking Group PLC (ARBB:LON), 1,065 | Avacta Group PLC (AVCT:LON), 50.8 | Burford Capital Limited (BUR:LON), 1,126 | Chamberlin plc (CMH:LON), 1.7 | City of London Investment Group PLC (CLIG:LON), 334 | Evgen Pharma Plc (EVG:LON), 0 | Gateley (Holdings) Plc (GTLY:LON), 123 | Genedrive Plc (GDR:LON), 3.4 | Koovs (KOOV:LON), 0 | Murgitroyd Group (MUR:LON), 0 | Woodbois Limited (WBI:LON), 0 | Primary Health Properties PLC (PHP:LON), 91.3 | R.E.A. Holdings plc (RE:LON), 70.0 | Redx Pharma Plc (REDX:LON), 21.5 | Scancell Holdings Plc (SCLP:LON), 10.2 | Surface Transforms PLC (SCE:LON), 9.6 | 600 Group PLC (SIXH:LON), 2.6 | Tissue Regenix Group plc (TRX:LON), 68.5 | Titon Holdings Plc (TON:LON), 80.0 | Oxford BioMedica plc (OXB:LON), 191 | ValiRx PLC (VAL:LON), 3.7
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
The Monthly
Time Finance plc (TIME:LON), 37.2 | Abzena (ABZA:LON), 0 | Advanced Oncotherapy Plc (AVO:LON), 1.9 | Allergy Therapeutics plc (AGY:LON), 2.7 | Alliance Pharma plc (APH:LON), 37.2 | Arbuthnot Banking Group PLC (ARBB:LON), 1,065 | Avacta Group PLC (AVCT:LON), 50.8 | Burford Capital Limited (BUR:LON), 1,126 | Chamberlin plc (CMH:LON), 1.7 | City of London Investment Group PLC (CLIG:LON), 334 | Evgen Pharma Plc (EVG:LON), 0 | Gateley (Holdings) Plc (GTLY:LON), 123 | Genedrive Plc (GDR:LON), 3.4 | Koovs (KOOV:LON), 0 | Murgitroyd Group (MUR:LON), 0 | Woodbois Limited (WBI:LON), 0 | Primary Health Properties PLC (PHP:LON), 91.3 | R.E.A. Holdings plc (RE:LON), 70.0 | Redx Pharma Plc (REDX:LON), 21.5 | Scancell Holdings Plc (SCLP:LON), 10.2 | Surface Transforms PLC (SCE:LON), 9.6 | 600 Group PLC (SIXH:LON), 2.6 | Tissue Regenix Group plc (TRX:LON), 68.5 | Titon Holdings Plc (TON:LON), 80.0 | Oxford BioMedica plc (OXB:LON), 191 | ValiRx PLC (VAL:LON), 3.7
- Published:
04 Apr 2018 -
Author:
Martin Hall -
Pages:
49
This month’s feature article is the first publication of the 2017 global pharmaceutical industry statistics from which the global and US rankings of the top 15 drug companies are derived. Comparisons are made with historical data to show how different company strategies have evolved. In addition, an analysis of the evolution of biopharmaceuical drugs has been made, together with a key sub-set, namely drugs derived from antibody technology, which now represent 12% of the entire market. Two more drugs joined the $100bn club in 2017.